Browsing Tag
Kisqali
3 posts
Novartis profit plunges 70% after $1.9bn drug impairment despite stronger core earnings
Novartis reported $14.52 billion in quarterly sales and an 11% increase in core operating profit, but statutory net income declined 70% following a major impairment related to its investigational medicine del-desiran. Strong oncology and immunology sales are helping offset generic competition, while the drug pipeline presents new financial uncertainties.
Novartis achieves 22% rise in core operating income, driven by innovative medicines
Novartis has reported a stellar performance for the fourth quarter of 2024, showcasing impressive growth across its core…
Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials
Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with…